In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price target of $4.00. The company’s shares opened today at $0.87.
According to TipRanks, White is an analyst with an average return of -10.5% and a 31.65% success rate. White covers the Healthcare sector, focusing on stocks such as SAB Biotherapeutics, TG Therapeutics, and InflaRx.
SAB Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, which is a 302.30% upside from current levels. In a report released on June 15, Chardan Capital also reiterated a Buy rating on the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
SABS market cap is currently $44.35M and has a P/E ratio of -1.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
- SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
- SAB Biotherapeutics to host rvirtual research and development day
- SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
- SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
- SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
